Initial experience with PulseRider (Pulsar Vascular) has shown the device to be safe and effective as an adjunct in the treatment of bifurcation aneurysms arising at the basilar apex or carotid terminus according to a report of the first three cases in the USA published in the Journal of NeuroInterventional Surgery.
InVivo Therapeutics has reopened subject enrolment for the company’s ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. To date, there have been no reported serious safety events with the study’s first subject, and InVivo has been cleared by the Data Safety Monitoring Board (DSMB) to move forward with the study.
Researchers at the Medical Research Council (MRC) Toxicology Unit have identified a protective mechanism that activates when body temperature is lowered, initiating a process that prevents the loss of brain cells and the connections between them.
Researchers have identified a beneficial immune response that occurs after injury to the central nervous system. By harnessing this response, researchers may be able to develop new and better treatments for brain and spinal cord injuries, and tools to predict how patients will respond to treatment, thus improving treatment of degenerative conditions.
Results from a preliminary study indicate that among patients with relapsing-remitting multiple sclerosis, treatment with nonmyeloablative hematopoietic stem cell transplantation (low intensity stem cell transplantation) was associated with improvement in measures of disability and quality of life, according to a study in the Journal of the American Medical Association.
InVivo Therapeutics has announced a three-month update for the first subject in the company’s ongoing pilot trial of its investigational Neuro-Spinal Scaffold in subjects with acute spinal cord injury. The Neuro-Spinal Scaffold was implanted in the subject in October 2014 at the Barrow Neurological Institute at St. Joseph’s Hospital and Medical Center in Phoenix, USA by Nicholas Theodore, chief of spinal surgery.
Research presented at the American Stroke Association’s International Stroke Conference (Nashville, USA, 11–13 February, 2015) suggests that a new device inserted into small ruptured brain aneurysms significantly improved healing of ruptured aneurysms compared to a standard device. The original clinical study (HydroCoil Endovascular aneurysm occlusion and Packing Study or HELPS) was funded by MicroVention.
A recently completed National Institutes of Health-funded trial confirms the efficacy of blood flow measurement technology from VasSol to predict the possibility of repeated stroke in at-risk individuals.
The American Heart Association/American Stroke Association (AHA/ASA) and Medtronic plc have agreed a collaboration to reduce the rate of recurrent strokes in the USA. The two organisations will work together over several years to educate, raise awareness and support effective management of patients who have strokes. The initiative, announced at the American Stroke Association’s annual International Stroke Conference (10–12 February, Nashville, Tennessee) will focus on reducing strokes of unknown cause—cryptogenic stroke.
The first patient has been enrolled in the RE-SPECT ESUS phase III study to investigate the efficacy and safety of dabigatran etexilate (Boehringer Ingelheim) for the prevention of recurrent embolic stroke of undetermined source (ESUS). RE-SPECT ESUS aims to include 6,000 patients in 35 countries.
For the first time, the Multicentre randomised clinical trial of endovascular treatment for acute ischaemic stroke in the Netherlands (MR CLEAN) has shown better outcomes in favour of intervention in patients with acute ischaemic stroke.
More than 70 teams composed of 568 students and entrepreneurs have been accepted to compete in the Neuro Startup Challenge, an open innovation competition designed to bring promising brain-related inventions to market. The challenge has teams competing to commercialise 16 National Institutes of Health-conceived and -developed inventions involving therapeutics, diagnostics, prognostics, and medical devices for a range of brain diseases.
Three-year outcomes from an ongoing clinical trial suggest that high-dose immunosuppressive therapy followed by transplantation of a person’s own blood-forming stem cells may induce sustained remission in some people with relapsing-remitting multiple sclerosis (RRMS). The trial is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and conducted by the NIAID-funded Immune Tolerance Network (ITN).
BrainScope Company has announced the publication of an independent study that demonstrated the potential clinical utility of its traumatic brain injury technology to identify acute stroke in the hospital Emergency Department setting. The results of this study, “Identification of Acute Stroke Using Quantified Brain Electrical Activity” were published in the peer-reviewed journal Academic Emergency Medicine authored by investigators from University Hospitals Case Medical Center, New York University School of Medicine, and The Johns Hopkins University School of Medicine, USA.
New research at the University of Cincinnati Neuroscience Institute has shown that spreading depolarisations can be measured by the placement of electroencephalograph (EEG) electrodes on the scalp. Head of the research team, Jed Hartings (research associated professor, Department of Neurosurgery, University of Cincinnati Neuroscience Institute, USA) speaks to NeuroNews about the discovery and its potential to change current practice.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos